Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : Politics for Pros- moderated -- Ignore unavailable to you. Want to Upgrade?

To: KLP who wrote (433480)	6/28/2011 4:44:51 PM
From: goldworldnet	Read Replies (1) \| Respond to of 794024

Here's another link about airport scanners at NPR. Your article specifically mentions basal cell carcinoma, which isn't lethal, but can mess up your face. I had basal cell carcinoma removed from my nose last year and need a second reconstructive operation. npr.org * * *

To: KLP who wrote (433480)	6/29/2011 2:12:21 PM
From: Pogeu Mahone	1 Recommendation Respond to of 794024

Of course, if TSA workers who are merely standing near the scanners are already developing cancer, frequent flyers are also putting themselves in harm’s way by standing directly inside the radiation-firing machines. ============================= Implant Sciences Signs Testing Agreements for Quantum Sniffer QS-B220 Explosives and Narcotics Trace Detector to Be Deployed at Airports and Air Cargo Facilities WILMINGTON, MA--(Marketwire - 06/27/11) - Implant Sciences Corporation (OTCQB: IMSC) (Pinksheets:IMSC - News), a high technology supplier of systems and sensors for homeland security markets, today announced it has signed agreements with key end-user sites in the United States, Asia, and South America to test its newly launched Quantum Sniffer™ QS-B220 bench-top explosives and narcotics trace detector. The systems will be deployed in actual operational environments in both airport security and air cargo screening facilities. "We are pleased with the enthusiastic response the QS-B220 is receiving from the user community. Containing no radioactive materials, Implant Sciences' products screen passengers and cargo without health or environmental risks," stated Implant Sciences CEO, Glenn D. Bolduc. Todd Silvestri, Vice President of Product Development added, "The QS-B220 has been designed to meet or exceed all TSA requirements. With automatic calibration, high throughput, and low maintenance needs, the system is ideally suited for security screening applications." About the Quantum Sniffer QS-B220 The QS-B220 Quantum Sniffer, introduced in May 2011, is a bench-top explosives and narcotics trace detector that uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, improvised, or homemade explosives and narcotic substances. The QS-B220 continues the Implant Sciences tradition of freedom from radioactive materials, low total cost of ownership, and high operational availability. About Implant Sciences Implant Sciences develops, manufactures and sells sophisticated sensors and systems for Security, Safety, and Defense (SS&D) markets. The Company has developed proprietary technologies used in its commercial explosive trace detection systems which ship to a growing number of locations domestically and internationally. Implant Sciences' QS-H150 Portable Explosives Detector has been designated as Qualified Anti-Terrorism Technology by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). For further details on the Company and its products, please visit the Company's website at www.implantsciences.com. Safe Harbor Statement This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that our explosives detection products and technologies (including any new products we may develop) may not be accepted by governments or by other law enforcement agencies or commercial consumers of security products; economic, political and other risks associated with international sales and operations could adversely affect our sales; our business is subject to intense competition and rapid technological change; liability claims related to our products or our handling of hazardous materials could damage our reputation and have a material adverse effect on our financial results; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including our most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements. Contact: Contact:Implant Sciences CorporationCompany Contact:Glenn Bolduc CEO978-752-1700 Email ContactorInvestor Contact:Laurel Moody646-810-0608Email finance.yahoo.com